3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
136
Lymphoma, T-Cell, Cutaneous
45
Lymphoma, Non-Hodgkin
37
Lymphoma, Follicular
36
Precursor Cell Lymphoblastic Leukemia-Lymphoma
35
Lymphoma, Large B-Cell, Diffuse
35
Lymphoma, Large-Cell, Immunoblastic
34
Leukemia, Lymphocytic, Chronic, B-Cell
34
Lymphoma, Mantle-Cell
33
Lymphoma, B-Cell, Marginal Zone
33
Burkitt Lymphoma
33
Lymphoma
32
Leukemia, Myeloid, Acute
32
Hodgkin Disease
31
Mycosis Fungoides
30
Sezary Syndrome
29
Multiple Myeloma
28
Leukemia, Myeloid, Accelerated Phase
26
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
24
Neoplasm Metastasis
24
Leukemia, Myeloid, Chronic-Phase
24
Leukemia
23
Myelodysplastic Syndromes
22
Lymphoma, Large-Cell, Anaplastic
22
Congenital Abnormalities
22
Blast Crisis
22
Skin Neoplasms
20
Immunoblastic Lymphadenopathy
20
Myeloproliferative Disorders
19
Recurrence
18
Interventions
Imatinib Mesylate
3
Ipilimumab
2
CTLA-4 Antigen
2
trastuzumab deruxtecan
1
ripretinib
1
pexidartinib
1
pembrolizumab
1
Thalidomide
1
Specimen Handling
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Injections
1
Fentanyl
1
Drug Therapy
1
Docetaxel
1
Cyclophosphamide
1
Blood Specimen Collection
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
Cyclophosphamide
×
Dermatologic
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled